Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Dimitrios Stefanoudakis(APLA Health), Konstantinos G. Toutouzas(National and Kapodistrian University of Athens), Nikolaos V. Michalopoulos(National and Kapodistrian University of Athens), Alexandra Drakaki(Columbia University Irving Medical Center), Dimitriοs Schizas(National and Kapodistrian University of Athens), Maximos Frountzas(National and Kapodistrian University of Athens)
Cited by 78
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k